Field Medical Appoints Mark A. Turco, MD, as New CEO to Lead Growth Initiatives

Field Medical Appoints Mark A. Turco, MD, as Chief Executive Officer

Field Medical, Inc., a cutting-edge company in the clinical-stage realm of medical technology, has recently elevated Dr. Mark A. Turco, MD, to the position of Chief Executive Officer. This prominent appointment, disclosed on March 16, 2026, is poised to propel the company into its next significant growth phase, especially as it continues to make strides in the development of second-generation pulsed field ablation (PFA) solutions tailored for intricate ventricular and atrial arrhythmias.

Dr. Turco's extensive career spans over three decades, during which he has amassed a wealth of experience across both startup environments and large-scale medical device organizations. His background includes leadership roles at several venture-backed cardiovascular startups, along with positions at notable global companies like Medtronic and Covidien. He is recognized for successfully guiding multiple clinical-stage firms through different stages of development and facilitating strategic transactions, a skill that will be invaluable for Field Medical as it expands its capabilities.

In a statement, Ben Cannon, a board member of Field Medical and part of the BioStar Capital and Cue Growth investment teams, expressed confidence in Dr. Turco’s unique qualifications. "His blend of experience as a cardiologist and a medtech executive uniquely positions him to lead Field Medical effectively. As we strive to enhance our clinical programs and operational capacities, Dr. Turco’s extensive knowledge in advancing sophisticated medical technologies will be essential for disciplined execution and sustainable value creation for the long term,” Cannon noted.

Prior to his appointment, Dr. Turco was the president and CEO of JC Medical, Inc., where he spearheaded the development of a transcatheter aortic valve replacement (TAVR) system specifically designed to tackle aortic regurgitation—an endeavor that was successfully acquired by Edwards Lifesciences in July 2024. Additionally, he has held senior executive roles within the vascular and neurovascular divisions at Medtronic, and most recently, he led the Rhode Island Life Science Hub. His dual expertise in clinical cardiology and operational management makes him an asset to Field Medical's leadership team.

Upon his appointment, Dr. Turco expressed enthusiasm about joining Field Medical at this pivotal point in its evolution. He remarked, “The company has engineered a distinct PFA platform with the capability to significantly relieve pressing patient needs concerning ventricular arrhythmias and atrial fibrillation. I am eager to collaborate intimately with the outstanding team at Field Medical to rigorously advance our clinical programs and navigate the regulatory landscape to accomplish our operational objectives.”

Founded in 2022, Field Medical is dedicated to pioneering advanced pulsed field ablation solutions aimed at addressing complex cardiac arrhythmias. The innovative FieldForce Ablation System employs a proprietary FieldBending™ energy technology designed to deliver efficient and accurate ablation with the goal of enhancing treatment results for patients with ventricular and atrial arrhythmias. Notably, in 2024, Field Medical achieved Breakthrough Device Designation and gained acceptance into the FDA’s TAP Pilot Program for its indication concerning ventricular tachycardia. Furthermore, the VCAS trial results were published in Circulation in October 2025, underscoring the company's commitment to clinical excellence.

In summary, Dr. Turco’s leadership represents a significant milestone for Field Medical as it embarks on reinforcing its operations and expanding its influence in the crucial field of cardiac care. He stands poised to play an instrumental role in shaping the future of the company and contributing positively to the healthcare landscape.

For more information about Field Medical and its initiatives, visit Field Medical's official website and follow them on platforms like LinkedIn, X, and YouTube. It is also worth noting that the FieldForce™ Ablation System remains an investigational device, subject to regulatory restrictions in the United States.